key: cord-0945424-u4dp92dz
authors: Frey, Sarah; Chowdhury, Reezwana; Connolly, Caoilfhionn M.; Werbel, William A.; Segev, Dorry L.; Parian, Alyssa M.; Tsipotis, Evangelos; Dudley-Brown, Sharon; Lazarev, Mark; Melia, Joanna M.; Truta, Brindusa; Yu, Huimin; Selaru, Florin M.
title: Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease
date: 2022-01-06
journal: Clin Gastroenterol Hepatol
DOI: 10.1016/j.cgh.2021.12.045
sha: 67a4aa9b47b98fcb89d68b389da05dd849591afb
doc_id: 945424
cord_uid: u4dp92dz

Patients with inflammatory bowel disease (IBD) are recommended to receive vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), regardless of their immunosuppression status. Immunosuppressive medications represent a mainstay of therapy in moderate to severe IBD; however, their impact on the SARS-CoV-2 vaccine response remains unclear. Studies thus far have shown that patients with IBD on various therapies had detectable antibody responses after standard vaccinations.1-5 To date, one study has examined the kinetics of antibody response at 3 months after vaccination in patients with IBD, but data beyond this time point are not yet available.6 The aim of this study was to assess anti-spike antibody response 6 months after completion of standard SARS-CoV-2 vaccination in patients with IBD. Secondarily, we observed antibody kinetics over 6 months in a subset of patients post-vaccination.

Patients with Inflammatory Bowel Disease (IBD) are recommended to receive vaccination against severe acute respiratory syndrome coronavirus 2, (SARS-CoV-2) regardless of their immunosuppression status.

Immunosuppressive medications represent a mainstay of therapy in moderate to severe IBD, however their impact on the SARS-CoV-2 vaccine response remains unclear. Studies thus far have shown that IBD patients on various therapies had detectable antibody responses after standard vaccinations. [1] [2] [3] [4] [5] To date, one study has examined the kinetics of antibody response at three months after vaccination in IBD patients, but data beyond this time point are not yet available. 6 The aim of this study was to assess antispike antibody response six months after completion of standard SARS-CoV-2 vaccination in IBD patients. Secondarily, we observed antibody kinetics over six months in a subset of patients' postvaccination.

IBD patients who received SARS-CoV-2 vaccination with either Pfizer, Moderna, or Johnson & Johnson (J&J), 18 years old and older were included. Participants provided informed consent prior to study entry.

Transplant patients, those with prior COVID-19 infection, and those who received additional vaccine doses were excluded. An electronic questionnaire was used to collect baseline demographics and clinical characteristics. Antibody titers were measured at one, three and six months after completion of vaccine series using the Roche Elecsys anti-SARS-CoV-2 enzyme immunoassay (EIA) (positive ≥ 0.8 U/mL, ceiling of 250 U/mL with later expansion to 2500 in U/mL in April 2021). The assay tests for antibodies against the spike protein receptor binding domain (RBD). As in our previous studies, low-positive antibody response was defined as anti-RBD pan Ig 0.8-50 units/mL; high antibody response was defined as anti-RBD pan Ig >50 units/mL based on plasma neutralizing capacity in COVID-19 convalescent patients as well as a modeling study across SARS-CoV-2 vaccine trials. -9 This study was approved by the Johns Hopkins Institutional Review Board (IRB00248540).

Of 75 patients with antibody titers at six months, 78% were female, with median (IQR) age of 45 (38, 58) ( Table 1) . Forty-three patients (57.3%) received Pfizer and 32 (42.7%) received Moderna. The majority of patients (n = 68, 90.7%) were on immunosuppressive medications; TNF-α inhibitors were the most commonly prescribed therapy (n=38; 50.7%). Twenty-nine patients (38.7%) were on combination therapy with TNF-α inhibitors and thiopurines, corticosteroids or methotrexate.

All 75 patients had a detectable antibody response at six months following SARS-CoV-2 vaccination with 59/75 patients (78.7%) having a high positive antibody response. Of those with low-positive antibody response at six months, 12/16 (75%) were on TNF-α inhibitors; 10/16 (63%) of these patients were on TNF-α inhibitor monotherapy.

In examining the association of TNF-inhibitors with antibody response, 12 out of 38 (31.6%) patients on TNF-α inhibitors had low-positive antibody response while 26/38 (68.4%) had high-positive antibody titers at six months. In contrast, nearly all participants on vedolizumab (6/6; 100%), tofacitinib (2/2; 100%) and ustekinumab (15/17; 88.2%) had high-positive antibody response. A greater proportion of patients on TNF-α inhibitors, either monotherapy or combination therapy, had low-positive antibody titers as compared to those on other immunosuppressive agents (12/16; 75% v. 4/16; 25%; p=0.048

Fisher's exact). A similar proportion of patients with low-positive and high-positive antibody response at six months were on glucocorticoids (5/16; 31.2% v. 18/59; 30.5%).

To assess for stability of antibody response, we compared 1-and 6-month antibody levels among the 45 persons with paired results. Most patients (37/45; 82.2%) with high antibody response at 1 month, maintained high antibody response at 6 months (Supplemental Table 2 ). Of the eight patients with highpositive antibody titers at one month that waned to low-positive at six months, 6/8 (75%) were on TNFα inhibitors and 6/8 (75%) received the Pfizer vaccine series (Supplemental Table 1 ). There was one This is the first study assessing antibody response six months after standard SARS-CoV-2 vaccination in IBD patients. All patients had detectable antibodies at six months with the majority (78.7%) having a high-positive antibody response. A recent study demonstrated a reduced humoral response in patients treated with TNF-α inhibitor monotherapy compared to healthy controls, and while our findings suggest that those on TNF-α inhibitors are more likely to have a lower antibody response at six months compared to patients on other immunosuppressive agents, a larger sample size to allow adjustment for confounding factors is required for further evaluation. 10 Limitations of this study include small sample size, and lack of racial and ethnic diversity. There were only a few participants included on vedolizumab, ustekinumab or tofacitinib which limits our assessment of antibody formation while on those medications. Due to small numbers, we were unable to control for vaccine, type, age and comorbidity. In addition, the dosing of corticosteroids was not available. We included patients without prior known COVID-19 infection, but as we did not complete antinucleocapsid testing, asymptomatic infection at any point in the study cannot be excluded.

Despite these limitations, this is the first available data on 6-month antibody response to SARS-CoV-2 vaccination in IBD patients. Our findings are reassuring for IBD patients receiving immunosuppressive therapy in that all patients in our study mounted an immune response to the SARS-CoV-2 vaccine.

Although the clinical significance of quantitative antibody titers is unknown, this data can help guide clinicians' recommendations on timing of SARS-CoV-2 vaccine booster doses.

J o u r n a l P r e -p r o o f Table 1 . Demographic and clinical characteristics of IBD patients after SARS-CoV-2 vaccination, stratified by anti-SARS-CoV-2 RBD antibody response after six months. Table 2 . Anti-spike antibody response six-months following two dose SARS-CoV-2 vaccine in patients with IBD, stratified by antibody response one month after two-dose mRNA vaccine series. N (%) Antibody-response after 6 months Low-Positive

Totals ( Low-positive antibody response was defined as anti-RBD pan Ig 0·8-50 units/mL.

High-positive antibody response was defined as anti-RBD pan Ig >50 units/mL.

Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls

Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease

Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study

Humoral immune response to mRNA COVID019 vaccines among patients with IBD

Serologic response to messenger RNA coronavirus disease 2019 vaccines in inflammatory bowel disease patients receiving biologic therapies

Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease

High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases

Food and Drug Administration emergency use authorization (EUA) for convalescent plasma. Secondary Food and Drug Administration emergency use authorization (EUA) for convalescent plasma 2021

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving TNF-α inhibitors

"prefer not to answer" for Hispanic/ Latino and 62 did not respond to the question about holding medications prior to vaccination. 3 Patients could select >1 medication, thus n>76 4 Hydroxychloroquine includes hydroxychloroquine and chloroquine. 5 Mycophenolate includes mycophenolic acid and mycophenolate mofetil. 6 Thiopurine includes azathioprine and 6-mercaptopurine. 7 TNF inhibitors include adalimumab, certolizumab, etanercept, golimumab, and infliximab. 8 Systemic corticosteroid includes prednisone and prednisone equivalents. 9 Other combination therapy includes 2 or more drugs listed above, excluding 5-ASAs. Regimens in this category included adalimumab and budesonide (n=2), budesonide, systemic corticosteroid, and vedolizumab(n=1), methotrexate, systemic corticosteroid, and ustekinumab (n=1), budesonide and ustekinumab (n=1), azathioprine and ustekinumab (n=2), azathioprine and ustekinumab (n=2), adalimumab and ustekinumab (n=1), mycophenolate and systemic corticosteroid (n=1) 10 Participants were surveyed with the question "Did you hold doses of your immunosuppressive medication(s) in the 2 weeks before receiving the vaccine?" 11 Participants also have diagnosis of systemic lupus erythematosus, Sjὅgren's syndrome, myositis, systemic sclerosis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, inflammatory bowel disease associated arthritis, polyarteritis nodosa, Behcet's syndrome, polymyalgia rheumatica, temporal arteritis, eosinophilic granulomatosis polyangiitis, granulomatous polyangiitis, Henoch-Schonlein purpura, microscopic polyangiitis, or Takayasu arteritis. 12 Calculated as days from 1st dose to testing for the patient who received the J&J vaccine. All 76 patients had antibody titers measured at 6 months, 63 patients had antibody titers